Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …

Calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide found mostly in
peptidergic sensory C-fibers, has been suggested to be implicated in the pathogenesis of …

Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials
(RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness …

Background and objectives The identification of predictors of response to antiCGRP mAbs
could favor tailored therapies and personalized treatment plans. This study is aimed at …

Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the
prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials …

Background In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in
chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their …

Objective To evaluate the long‐term effectiveness, safety, and tolerability of erenumab in a
real‐world migraine population, looking for putative predictors of responsiveness …

Background Criteria, including clinical features and effective outcomes, for access and
persistence of novel but costly treatments may vary between countries, thus affecting the …

Background Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a
favourable option for patients with migraine who experience distressful headache disability …

Background and purpose A rapid response to preventive therapy is of pivotal importance in
severely disabled patients with chronic migraine (CM) and diverse preventive treatment …